Functional DNA Repair Signature of Cancer Cell Lines Exposed to a Set of Cytotoxic Anticancer Drugs Using a Multiplexed Enzymatic Repair Assay on Biochip

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Forestier, Anne ^a   Sarrazy, Fanny ^a   Caillat, Sylvain ^a   Vandenbrouck, Yves ^a   Sauvaigo, Sylvie ^a  

^a CEA GRENOBLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; OXALIPLATIN;

ARTICLE; BIOCHIP; CANCER CELL CULTURE; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYMATIC ASSAY; FEMALE; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; MULTIPLEXED ENZYMATIC REPAIR ASSAY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DNA DAMAGE; DNA REPAIR; HUMANS; NEOPLASMS; TRANSCRIPTOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84871757072     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051754     Document Type: Article

References (51)

1. Zhou BB, Elledge SJ, (2000) The DNA damage response: putting checkpoints in perspective. Nature 408: 433-439.
2. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316: 1160-1166.
3. Fojo T, (2001) Cancer, DNA repair mechanisms, and resistance to chemotherapy. J Natl Cancer Inst 93: 1434-1436.
4. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC, (1997) Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57: 850-856.
5. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762.
6. Brosh R, Rotter V, (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9: 701-713.
7. Jung HJ, Kim EH, Mun JY, Park S, Smith ML, et al. (2007) Base excision DNA repair defect in Gadd45a-deficient cells. Oncogene 26: 7517-7525.
8. Lange SS, Vasquez KM, (2009) HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic. Mol Carcinog 48: 571-580.
9. Nouspikel T, (2009) DNA repair in mammalian cells: Nucleotide excision repair: variations on versatility. Cell Mol Life Sci 66: 994-1009.
10. Krokan HE, Nilsen H, Skorpen F, Otterlei F, Slupphaug G, (2000) Base excision repair of DNA in mammalian cells. FEBS Let 476: 73-77.
11. Wood RD, (1997) Nucleotide excision repair in mammalian cells. J Biol Chem 272: 23465-23468.
12. Ischenko AA, Saparbaev MK, (2002) Alternative nucleotide incision repair pathway for oxidative DNA damage. Nature 415: 183-187.
13. Almeida KH, Sobol RW, (2007) A unified view of base excision repair: Lesion-dependent protein complexes regulated by post-translational modification. DNA repair 6: 695-711.
14. Reardon JT, Bessho T, Kung HC, Bolton PH, Sancar A, (1997) In vitro repair of oxidative DNA damage by human nucleotide excision repair system: Possible explanation for neurodegeneration in Xeroderma pigmentosum patients. Proc Natl Acad Sci USA 94: 9463-9468.
15. Klungland A, Höss M, Gunz D, Constantinou A, Clarkson SG, et al. (1999) Base excision repair of oxidative DNA damage activated by XPG protein. Mol Cell 3: 33-42.
16. Couvé S, Macé-Aimé G, Rosselli F, Saparbaev MK, (2009) The human oxidative DNA glycosylase NEIL1 excises psoralen-induced interstrand DNA cross-links in a three-stranded DNA structure. J Biol Chem 284: 11963-11970.
17. Wang X, Peterson CA, Zheng H, Nairn RS, Legerski RJ, et al. (2001) Involvement of nucleotide excision repair in a recombination-independent and error-prone pathway of DNA interstrand cross-link repair. Mol Cell Biol 21: 713-720.
18. Zheng H, Wang X, Legerski RJ, Glazer PM, Li L, (2006) Repair of DNA interstrand cross-links: interactions between homology-dependent and homology-independent pathways. DNA repair 5: 566-574.
19. Ljungman M, (2009) Targeting the DNA damage response in cancer. Chem Rev 109: 2929-2950.
20. Mohammed MZ, Vyjayanti VN, Laughton CA, Dekker LV, Fischer PM, et al. (2011) Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer 104: 653-663.
21. Robert J, Vekris A, Pourquier P, Bonnet J, (2004) Predicting drug response based on gene expression. Crit Rev Oncol Hematol 51: 205-227.
22. Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, et al. (2004) Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res 64: 356-362.
23. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244.
24. Swanton C, Szallasi Z, Brenton JD, Downward J, (2008) Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. Breast Cancer Res 10: 214.
25. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227-235.
26. McDermott U, Downing JR, Stratton MR, (2011) Genomics and the continuum of cancer care. N Engl J Med 364: 340-350.
27. Paz-Elizur T, Sevilya Z, Leitner-Dagan Y, Elinger D, Roisman LC, et al. (2008) DNA repair of oxidative DNA damage in human carcinogenesis: Potential application for cancer risk assessment and prevention. Cancer Lett 266: 60-72.
28. Bohanes P, Labonte MJ, Lenz HJ, (2011) A review of excision repair cross-complementation group 1 in colorectal cancer. Clin Colorectal Cancer 10: 157-164.
29. Sander M, Van Houten B, (2006) Integrating multiple views of the cell: DNA repair jumps to higher level at Stowe workshop. DNA repair 5: 523-527.
30. Stracker TH, Usui T, Petrini JH, (2009) Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst) 8: 1047-1054.
31. Morris JR, (2010) More modifiers move on DNA damage. Cancer Res 70: 3861-3863.
32. Pons B, Belmont AS, Masson-Genteuil G, Chapuis V, Oddos T, et al. (2010) Age-associated modifications of Base Excision Repair activities in human skin fibroblast extracts. Mech Ageing Dev 131: 661-665.
33. Prunier C, Masson-Genteuil G, Ugolin N, Sarrazy F, Sauvaigo S, (2012) Aging and photo-aging DNA repair phenotype of skin cells-Evidence toward an effect of chronic sun-exposure. Mutat Res 736: 48-55.
34. Sauvaigo S, Caillat S, Odin F, Nkengne A, Bertin C, et al. (2010) Effect of aging on DNA excision/synthesis repair capacities of human skin fibroblasts. J Invest Dermatol 130: 1739-1741.
35. Liscovitch M, Ravid D, (2007) A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett 245: 350-352.
36. Millau JF, Raffin AL, Caillat S, Claudet C, Arras G, et al. (2008) A microarray to measure repair of damaged plasmids by cell lysates. Lab Chip 8: 1713-1722.
37. Branham WS, Melvin CD, Han T, Desai VG, Moland CL, et al. (2007) Elimination of laboratory ozone leads to a dramatic improvement in the reproducibility of microarray gene expression measurements. BMC Biotechnol 7: 8.
38. Drablos F, Feyzi E, Aas PA, Vaagbo CB, Kavli B, et al. (2004) Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair (Amst) 3: 1389-1407.
39. Middleton MR, Margison GP, (2003) Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol 4: 37-44.
40. Pommier Y, Leo E, Zhang H, Marchand C, (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17: 421-433.
41. Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM, (2006) Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 66: 4863-4871.
42. Wang D, Lippard SJ, (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320.
43. Du Puch CB, Barbier E, Kraut A, Coute Y, Fuchs J, et al. (2011) TOX4 and its binding partners recognize DNA adducts generated by platinum anticancer drugs. Arch Biochem Biophys 507: 296-303.
44. Li LS, Morales JC, Veigl M, Sedwick D, Greer S, et al. (2009) DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. Br J Pharmacol 158: 679-692.
45. Wyatt MD, Wilson DM 3rd, (2009) Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 66: 788-799.
46. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, et al. (2008) The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet Chapter 10: Unit 10 11.
47. Sengupta S, Harris CC, (2005) p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6: 44-55.
48. Jover R, Zapater P, Castells A, Llor X, Andreu M, et al. (2009) The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 45: 365-373.
49. Sinicrope FA, (2010) DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol 7: 174-177.
50. Darzynkiewicz Z, Traganos F, Wlodkowic D, (2009) Impaired DNA damage response-an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy. Eur J Pharmacol 625: 143-150.
51. Helleday T, (2010) Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 31: 955-960.